# De-escalation Radiation Strategy After NAC in Combination With ICI in LAHNSCC

> **NCT06572514** · PHASE1,PHASE2 · RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Locally Advanced Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** immunotherapy：pembrolizumab；chemo：albumin-bound paclitaxel and cisplatin

## Key facts

- **NCT ID:** NCT06572514
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-17
- **Primary completion:** 2026-09
- **Final completion:** 2027-04
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06572514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06572514, "De-escalation Radiation Strategy After NAC in Combination With ICI in LAHNSCC". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06572514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*